SGMTSagimet Biosciences Inc.

Nasdaq www.sagimet.com


$ 4.56 $ 0.16 (3.64 %)    

Thursday, 09-May-2024 10:50:42 EDT
QQQ $ 441.29 $ 0.83 (0.19 %)
DIA $ 392.61 $ 2.50 (0.64 %)
SPY $ 519.33 $ 1.89 (0.37 %)
TLT $ 90.20 $ 0.16 (0.18 %)
GLD $ 216.28 $ 1.55 (0.72 %)
$ 4.44
$ 4.40
$ 0.00 x 0
$ 0.00 x 0
$ 4.38 - $ 4.56
$ 2.13 - $ 20.71
312,845
na
46.44M
$ 4.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-25-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-21-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sagimet-announces-oral-presentation-of-data-from-the-phase-2b-fascinate-2-study-of-denifanstat-in-mash-at-easl-international-liver-congress-2024

Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...

 sagimet-biosciences-announces-appointment-of-thierry-chauche-as-chief-financial-officer-effective-may-6-2024

Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...

 hc-wainwright--co-initiates-coverage-on-sagimet-biosciences-with-buy-rating-announces-price-target-of-32

HC Wainwright & Co. analyst Ed Arce initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announ...

 sagimet-biosciences-announces-completion-of-phase-1-hepatic-impairment-study-with-fasn-inhibitor-denifanstat

Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid syntha...

 goldman-sachs-maintains-buy-on-sagimet-biosciences-lowers-price-target-to-27

Goldman Sachs analyst Andrea Tan maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and lowers the price target from $37...

 why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

 leerink-partners-initiates-coverage-on-sagimet-biosciences-with-outperform-rating-announces-price-target-of-26

Leerink Partners analyst Thomas Smith initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Outperform rating and a...

 jmp-securities-maintains-market-outperform-on-sagimet-biosciences-lowers-price-target-to-46

JMP Securities analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the...

 why-fmc-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fo...

 why-intel-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth q...

 kla-reports-q2-results-joins-visa-western-digital-and-other-big-stocks-moving-lower-in-fridays-pre-market-session

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Friday.

 texas-instruments-reports-q4-results-joins-blackberry-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Wednesday.

 sagimet-biosciences-begins-public-offering-of-9m-shares-of-its-series-a-common-stock

All of the shares in the proposed offering are to be sold by Sagimet. In addition, Sagimet expects to grant the underwriters a ...

 why-3m-shares-are-trading-lower-by-over-12-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-q...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION